{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-25-000011","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.469321+00:00","generated_at":"2026-05-26T03:26:03.987165+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025","bullets":["Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.","GAAP net income Q4 $7M ($0.05 EPS); full year $42M. Cash $104M at Dec 31, net cash $86M.","2025 outlook: net sales growth at least high single-digits, Adjusted EBITDA margin above 20%.","SG&A increased to $61M in Q4 from $54M a year ago; CEO cites Medicare disruption but remains confident."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-25-000011","json":"https://secwatch.observer/filing/0001376339-25-000011.json","markdown":"https://secwatch.observer/filing/0001376339-25-000011.md","text":"https://secwatch.observer/filing/0001376339-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000011/0001376339-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000011/mdxg-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:26:03.987165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}